Paroxysmal Nocturnal Haemoglobinuria (PNH) Dr Conal McConville ...

More documents

Recommendations

Info

SOLIRIS ® ▼(eculizumab) • Soliris® is indicated for the treatment of patients with paroxysmal nocturnal haemoglobinuria. Evidence of clinical benefit of Soliris® in the treatment of patients with <strong>PNH</strong> is limited to patients with history of transfusions. August_12_2010Gbl 26
SOLIRIS ® Blocks Terminal Complement Complement Cascade SOLIRIS® C3 C3a • SOLIRIS® binds with high affinity to C5 Proximal C3b • Terminal complement - C5a and C5b-9 activity blocked C5 C5a • Proximal functions of complement remain intact Terminal C5b C5b-9 Cause of Haemolysis in <strong>PNH</strong> • Weak anaphylatoxin • Immune complex clearance • Microbial opsonization 1. Figueroa JE, Densen P. Clin Microbiol Rev. 1991;4(3):359-395. 2. Walport MJ. N Engl J Med. 2001;344(14):1058-66. 3. SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 4. Rother RP et al. Nature Biotech. 2007;25(11):1256-64. August 12_10_2010Gbl 27
Page 1 and 2: Paroxysmal Nocturnal Haemoglobinuri
Page 3 and 4: Paroxysmal Nocturnal Haemoglobinuri
Page 5 and 6: The Defect in PNH The Somatic Mutat
Page 7 and 8: PNH is a Progressive Disease of Chr
Page 9 and 10: Thrombosis Chronic Kidney Disease F
Page 23 and 24: Common Symptoms of Haemolysis Signa
Page 25: Historical Management of PNH Bone M
Page 29 and 30: Adverse Reactions Reported in ≥ 5
Page 31: August 12_10_2010Gbl Thank you Than

Paroxysmal Nocturnal Haemoglobinuria (PNH) Dr Conal McConville ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?